R S Bedlack

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. doi request reprint Amyotrophic lateral sclerosis: current practice and future treatments
    Richard S Bedlack
    Neurology Section, Division of Neurology, Duke University, Durham Veterans Affairs Medical Center, Durham, North Carolina 27707, USA
    Curr Opin Neurol 23:524-9. 2010
  2. ncbi request reprint MNGIE neuropathy: five cases mimicking chronic inflammatory demyelinating polyneuropathy
    Richard S Bedlack
    Division of Neurology, Duke University Medical Center, 932 Morreene Road, Box 3333, Durham, North Carolina 27707, USA
    Muscle Nerve 29:364-8. 2004
  3. doi request reprint Modifiable barriers to enrollment in American ALS research studies
    Richard S Bedlack
    Duke University and Durham Veterans Affairs Medical Center, 932 Morreene Rd, Durham, NC 27702, USA
    Amyotroph Lateral Scler 11:502-7. 2010
  4. ncbi request reprint How to handle myasthenic crisis. Essential steps in patient care
    R S Bedlack
    Duke University School of Medicine, Durham, North Carolina 27713, USA
    Postgrad Med 107:211-4, 220-2. 2000
  5. doi request reprint Open-label pilot trial of levetiracetam for cramps and spasticity in patients with motor neuron disease
    Richard S Bedlack
    Duke University Medical Center, Durham, North Carolina 27702, USA
    Amyotroph Lateral Scler 10:210-5. 2009
  6. ncbi request reprint Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis
    Richard S Bedlack
    Duke University Medical Center, Box 3333, Durham NC 27705, USA
    Expert Opin Emerg Drugs 12:229-52. 2007
  7. ncbi request reprint Quantitative myasthenia gravis score: assessment of responsiveness and longitudinal validity
    R S Bedlack
    Duke University Medical Center and Durham VAMC, Durham, NC, USA
    Neurology 64:1968-70. 2005
  8. ncbi request reprint Apolipoprotein E and neuromuscular disease: a critical review of the literature
    R S Bedlack
    PO Box 3403, Duke University Medical Center, Durham, NC 27710, USA
    Arch Neurol 57:1561-5. 2000
  9. ncbi request reprint APOE genotype is a risk factor for neuropathy severity in diabetic patients
    R S Bedlack
    Division of Neurology, Duke University Medical Center, Durham, NC 27705, USA
    Neurology 60:1022-4. 2003
  10. ncbi request reprint Does this patient have myasthenia gravis?
    Katalin Scherer
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    JAMA 293:1906-14. 2005

Collaborators

Detail Information

Publications20

  1. doi request reprint Amyotrophic lateral sclerosis: current practice and future treatments
    Richard S Bedlack
    Neurology Section, Division of Neurology, Duke University, Durham Veterans Affairs Medical Center, Durham, North Carolina 27707, USA
    Curr Opin Neurol 23:524-9. 2010
    ..More than 1700 articles with the phrase 'amyotrophic lateral sclerosis' have been published in the past 2 years; these form the basis for this timely review...
  2. ncbi request reprint MNGIE neuropathy: five cases mimicking chronic inflammatory demyelinating polyneuropathy
    Richard S Bedlack
    Division of Neurology, Duke University Medical Center, 932 Morreene Road, Box 3333, Durham, North Carolina 27707, USA
    Muscle Nerve 29:364-8. 2004
    ..In fact, three patients were actually treated for chronic inflammatory demyelinating polyneuropathy (CIDP). We discuss findings that may help distinguish patients with MNGIE from those with CIDP...
  3. doi request reprint Modifiable barriers to enrollment in American ALS research studies
    Richard S Bedlack
    Duke University and Durham Veterans Affairs Medical Center, 932 Morreene Rd, Durham, NC 27702, USA
    Amyotroph Lateral Scler 11:502-7. 2010
    ..Also included are patient concerns about the cost of participation, and confusion about several aspects of studies being offered. Along with prior work, these data suggest specific steps that can be taken to improve enrollment...
  4. ncbi request reprint How to handle myasthenic crisis. Essential steps in patient care
    R S Bedlack
    Duke University School of Medicine, Durham, North Carolina 27713, USA
    Postgrad Med 107:211-4, 220-2. 2000
    ..Because management of crisis includes treatment of the underlying myasthenia gravis, a neurologist should share in any decisions regarding care...
  5. doi request reprint Open-label pilot trial of levetiracetam for cramps and spasticity in patients with motor neuron disease
    Richard S Bedlack
    Duke University Medical Center, Durham, North Carolina 27702, USA
    Amyotroph Lateral Scler 10:210-5. 2009
    ....
  6. ncbi request reprint Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis
    Richard S Bedlack
    Duke University Medical Center, Box 3333, Durham NC 27705, USA
    Expert Opin Emerg Drugs 12:229-52. 2007
    ..These are described and prioritized herein, and suggestions are offered for efficiently sifting through them...
  7. ncbi request reprint Quantitative myasthenia gravis score: assessment of responsiveness and longitudinal validity
    R S Bedlack
    Duke University Medical Center and Durham VAMC, Durham, NC, USA
    Neurology 64:1968-70. 2005
    ..Our results support QMG use for assessing clinical change in trials...
  8. ncbi request reprint Apolipoprotein E and neuromuscular disease: a critical review of the literature
    R S Bedlack
    PO Box 3403, Duke University Medical Center, Durham, NC 27710, USA
    Arch Neurol 57:1561-5. 2000
    ..The effect of various APOE alleles on neuromuscular diseases therefore parallels their influence on central nervous system diseases. Arch Neurol. 2000;57:1561-1565..
  9. ncbi request reprint APOE genotype is a risk factor for neuropathy severity in diabetic patients
    R S Bedlack
    Division of Neurology, Duke University Medical Center, Durham, NC 27705, USA
    Neurology 60:1022-4. 2003
    ..Considering genotype alone, patients with APOE 3/4 and 4/4 genotypes had 3 more NISLL points than patients with other genotypes. This impact on severity is equivalent to having 15 extra years of age or diabetes duration...
  10. ncbi request reprint Does this patient have myasthenia gravis?
    Katalin Scherer
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    JAMA 293:1906-14. 2005
    ..Clinicians must be able to diagnose myasthenia gravis, since delays in establishing the diagnosis may put patients at risk for complications from this treatable disease...
  11. doi request reprint Factors associated with survival in the National Registry of Veterans with ALS
    Daniel M Pastula
    School of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Amyotroph Lateral Scler 10:332-8. 2009
    ..This finding could be due to a common exposure, a shared characteristic, an unmeasured confounder, or an enrollment bias. More research will be needed to understand the reasons behind this new finding...
  12. doi request reprint The National Registry of Veterans with amyotrophic lateral sclerosis
    K D Allen
    Epidemiology Research and Information Center, Durham VAMC, NC 27705, USA
    Neuroepidemiology 30:180-90. 2008
    ..This article describes the objectives, methods, and sample involved in the registry...
  13. ncbi request reprint Steroid treatment for myasthenia gravis: steroids have an important role
    Richard S Bedlack
    Division of Neurology, Duke University Medical Center, Trent Drive, Room 0395, Box 3403, Durham, North Carolina 27710 0001, USA
    Muscle Nerve 25:117-21. 2002
  14. doi request reprint Scrutinizing enrollment in ALS clinical trials: room for improvement?
    Richard S Bedlack
    Duke University Medical Center, Durham, NC, USA
    Amyotroph Lateral Scler 9:257-65. 2008
    ..Patient factors' and 'physician factors' may play more important roles in influencing enrollment, as in oncology trials. Our survey data support this idea, and provide potential mechanisms for improving enrollment...
  15. pmc Amyotrophic lateral sclerosis: an emerging era of collaborative gene discovery
    Katrina Gwinn
    National Institute for Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS ONE 2:e1254. 2007
    ..This resource should facilitate genetic discoveries which we anticipate will ultimately provide a better understanding of the biological mechanisms of neurodegeneration in ALS...
  16. pmc Creatine monohydrate in ALS: effects on strength, fatigue, respiratory status and ALSFRS
    Jeffrey Rosenfeld
    The Carolinas Neuromuscular ALS Center, Charlotte North Carolina, Carolinas Medical Center, USA
    Amyotroph Lateral Scler 9:266-72. 2008
    ..The trend toward improved survival was also found in another recently completed blinded trial using creatine monohydrate. Further investigation on the possible survival benefit of creatine in this patient population is ongoing...
  17. pmc Lithium may slow progression of amyotrophic lateral sclerosis, but further study is needed
    Richard S Bedlack
    Proc Natl Acad Sci U S A 105:E17; author reply E18. 2008
  18. ncbi request reprint Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial
    Paul H Gordon
    Department of Neurology, Columbia University, New York, NY, USA
    Lancet Neurol 6:1045-53. 2007
    ..Several trials are planned or are in progress to assess whether minocycline slows human neurodegeneration. We aimed to test the efficacy of minocycline as a treatment for amyotrophic lateral sclerosis (ALS)...
  19. ncbi request reprint Dysarthria and dysphagia from light chain amyloidosis
    Khalid Tabbarah
    Division of Neurology, Department of Medicine, Duke University Medical Center, PO Box 2905, Durham, NC 27710, USA
    Neurology 65:1671. 2005
  20. doi request reprint Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis
    Merit E Cudkowicz
    Neurology Clinical Trials Unit, Massachusetts General Hospital, 13th Street, Charlestown, MA 02129, USA
    Muscle Nerve 38:837-44. 2008
    ..Arimoclomol CSF levels increased with dose. Arimoclomol was shown to be safe, and it crosses the blood-brain barrier. Serum pharmacokinetic profiles support dosing of three times per day. An efficacy study in ALS is planned...